Chester County News and Community Website
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said preliminary 12-month data from its Phase 2 ArMaDa clinical trial showed meaningful reductions in disease progression for patients with geographic atrophy, a …
Ocugen (NASDAQ: OCGN) Reports Strong Midstage Data for Gene Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) said newly published clinical trial data support the safety and early effectiveness of its experimental gene therapy for Stargardt disease, a rare inherited …
Gene Therapy Slows Vision Loss in Stargardt Trial, Fueling Hope for First Treatment Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) is moving toward what could be a defining year, with a late-stage pipeline aimed at some of the most underserved rare skin …
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it has dosed the first patient in its global Phase 3 clinical program evaluating YCANTH (VP-102) for the treatment of …
Verrica Doses First Patient in Phase 3 Wart Trial, Eyes Major Label Expansion Read More
WAYNE, PA — Aclaris Therapeutics Inc. (NASDAQ: ACRS) said positive interim data from its first-in-human study of ATI-052 are accelerating the experimental drug’s push toward later-stage trials, signaling what the …
Early Trial Data Puts Aclaris’ ATI-052 on Fast Track Toward Bigger Bets Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will begin enrolling patients in January 2026 in a large, long-term study designed to assess whether its experimental Parkinson’s disease …
Annovis Launches 3-Year Parkinson’s Study to Test Long-Term Promise of Drug Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said the U.S. Food and Drug Administration has granted Fast Track designation to QTORIN™ rapamycin for the treatment of angiokeratomas, a rare …
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported positive topline results from a mid-stage clinical trial that positions its lead drug candidate as a potential first approved treatment for …
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program has announced new funding aimed at improving treatment and care delivery for people living with metastatic, or …
New Research Funding Targets Gaps in Care for Stage Four Breast Cancer Read More MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) unveiled new clinical data suggesting its investigational therapy buntanetap may reverse cognitive decline in Parkinson’s disease patients who also exhibit Alzheimer’s-related amyloid …
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline Read More